These results indicate that at 1-year follow-up, CTEPH patients present with substantial changes in the expression of CCR6, cytokines and activation markers in CD4+ and CD8+ T cells, compared to baseline. This evidence concerns the gene CD8A and chronic thromboembolic pulmonary hypertension.